



maxonis

NERVE REPAIR SOLUTIONS

From structural repair to functional recovery

Building the biological engine for nerve regeneration



Born from Decades of Nerve Regeneration Research

Prof. Shimon Rochkind's decades of clinical experience and nerve-regeneration research laid the scientific foundation for Maxonis and LDP-916

15+

YEARS OF
DEDICATED
RESEARCH &
CLINICAL
EXPERIENCE

1

15+ YEARS OF CLINICAL & SCIENTIFIC EXPERIENCE

Peripheral nerve repair and regeneration expertise.

2


BIOLOGICAL FOUNDATION

Research into laminin and key signals involved in axonal growth and nerve regeneration.

3

TRANSLATED INTO LDP-916

Scientific insights translated into Maxonis' lead nerve-regeneration technology.



Prof. Shimon Rochkind, MD, PhD

Decades of nerve-regeneration research became the scientific foundation for Maxonis.

The Challenge

Restoring function following nerve injury

One of medicine's greatest unmet needs



WHY IT MATTERS



Permanent functional loss

Nerve injuries can disrupt critical neural connections. Existing treatments may provide structural repair, but functional recovery often remains limited



Persistent pain & disability

More than **200M** people live with nerve-related disabilities



Current solutions fall short

PNI products exist, but functional recovery remains incomplete.
In SCI, no approved regenerative therapy exists.
regenerative therapy exists

THE OPPORTUNITY



Restore function — not just repair the nerve

True nerve regeneration could redefine outcomes in nerve injury care




Our solution

A bioactive peptide-hydrogel therapy designed to drive nerve regeneration




Two lead indications:
PNI + SCI



Peripheral Nerve Injury (PNI)

Delivered into commercial nerve conduits during surgery

- ✓ Designed to actively promote nerve regeneration beyond passive gap bridging
- ✓ Targets challenging nerve gaps where existing solutions remain limited



Spinal Cord Injury (SCI)


Delivered directly at the injury site

- ✓ Meaningful functional recovery demonstrated in preclinical models
- ✓ Addresses an indication with no approved regenerative therapy



LDP-916, A Proprietary Laminin Peptide

LDP-916 extracts the most potent signal inducers of the Laminin, a key protein to nerve repair, into a precision-peptide therapeutic, that actively enhances regeneration



Laminin

A natural extracellular
matrix protein

LDP-916

Precision-engineered
regenerative peptide

LDP-916

Peptide-hydrogel
injectable therapy



How LDP-916 Activates the Body's Regenerative Mechanism



LDP-916 activates and enhances the body's own biological regenerative mechanism



Built on Decades of Nerve Regeneration Research

Maxonis' scientific foundation combines world-class research in nerve regeneration with deep expertise in translating biological insight into therapeutic innovation.

SCIENTIFIC FOUNDATION

Rooted in decades of nerve-regeneration research

Our technology is based on extensive clinical and research experience in nerve repair and regeneration, and on biological mechanisms involved in axonal growth and functional recovery.

PRECLINICAL RESEARCH^x

Encouraging functional-recovery findings across two injury models

PNI

PERIPHERAL NERVE INJURY (PNI)

Sensory function recovery demonstrated in a peripheral nerve injury model.

SCI

SPINAL CORD INJURY (SCI)

Motor function recovery demonstrated in a spinal cord injury model.



Founding Team

Experienced operators in nerve repair, biomaterials, and biotech commercialization



Co-Founder & CEO

Itay Itzhaky

Health-tech executive with >
[\\$270M in exits \(ColBar → J&J, Datum Dental → Dentsply\)](#)

Expertise in scaling regenerative products, regulatory strategy, and commercialization



Co-Founder & CMO

Prof. Shimon Rochkind ,MD, PhD

World leader in nerve regeneration & microsurgery

Former Head of Peripheral Nerve Reconstruction at TLV Medical Center and Tel-Aviv University;
80+ publications



Co-Founder & CTO of Maxonis

Dr. Arie Goldlust PhD

Biochemist & biomaterials innovator;
co-founded Datum Dental (acquired by Dentsply)

Deep experience in formulation, CMC, and regenerative product development





Advancing the Future of Nerve Regeneration

Maxonis is developing an innovative peptide-hydrogel approach to support nerve regeneration

Let's explore opportunities to advance nerve regeneration together



www.maxonis.com



itayi@maxonis.com